Portal Innovations

Synaptrix is committed to offering free of drugs, lasting alternatives for postoperative pain treatment using NOVABLOC.

CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable and targeted ADC therapeutics. This approach aims to improve the efficacy and safety profiles of cancer therapies, offering potential advancements in the treatment landscape. By leveraging its unique dual linker payload technology, CrossBridge Bio seeks to revolutionize how cancer is treated, providing new options for patients and healthcare providers.

March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. The company's lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Alnair Therapeutics is a preclinical stage precision oncology platform dedicated to developing innovative treatments for difficult-to-treat malignancies. The company has pioneered a unique drug delivery technology that utilizes the distinct characteristics of cancer metabolism to enhance the targeting and penetration of therapeutic agents directly into cancer cells. This approach aims to improve treatment outcomes for patients, positioning Alnair Therapeutics as a potential leader in the field of cancer treatment.

Dimension Inx Corp. focuses on designing and developing three-dimensional (3D) printable materials and painted objects for research and commercial applications. The company specializes in creating regenerative microenvironments that aid the body in self-healing. Its biomaterials platform incorporates a complex interplay of material composition, microstructure, and microarchitecture to enhance biofunctionality. Dimension Inx offers a range of products, including Hyperelastic Bone for bone regeneration, 3D printable elastomers, bioactive ceramics, and solutions for soft tissue regeneration. Founded in 2016 and based in Chicago, Illinois, the company aims to provide innovative therapeutic products that restore tissue and organ function, potentially reducing the need for organ transplantation through advanced bio-fabrication processes.

Syntis Bio is a late-stage preclinical company focused on developing a new class of oral therapies. By utilizing innovative formulations, the company's drugs are designed to target specific tissues, which enhances bioavailability and expands treatment options across a broader range of diseases.

Cardiosense develops a physiological waveform AI platform aimed at creating predictive biomarkers for the detection and treatment of cardiac diseases. The company utilizes raw biosignals and advanced signal processing techniques to gain insights into cardiac functions and identify pre-symptomatic markers of cardiac conditions. By leveraging multi-sensor devices and proprietary algorithms, Cardiosense focuses on non-invasive monitoring solutions that enhance healthcare professionals' ability to analyze cardiac health data and track patient well-being. This innovative approach facilitates early detection of diseases, ultimately aiming to improve patient outcomes in cardiac care.

ClostraBio, Inc. is a biotech company based in Chicago, Illinois, founded in 2016. The company focuses on developing therapeutics to prevent allergic reactions to food by leveraging the gut microbiome. ClostraBio's research emphasizes the role of intestinal microbes in enhancing gut barrier function and regulating allergic sensitization to food. By creating microbiome-modulating therapeutics, including small-molecule formulations and dietary fibers, ClostraBio aims to provide effective treatments for individuals suffering from life-threatening food allergies. The company is committed to advancing the understanding of the microbiome's protective capabilities and discovering new ways to manage food allergies and related immune system disorders.

Rhaeos is a pioneering company that has developed the first wearable shunt monitor to enhance care for patients with hydrocephalus. Utilizing a novel thermal biosensor, the device allows for noninvasive, real-time monitoring of cerebrospinal fluid flow. This innovative technology, born from collaborative research at Northwestern University involving experts from engineering, medicine, and management, addresses a significant clinical need by providing timely data to improve treatment for chronic medical conditions. Rhaeos's patches are designed to detect fluid flow in various bodily systems, including blood and lymph, facilitating quicker medical responses and advancing the standard of care in neurosurgery and beyond.

Grove Biopharma is a biotechnology company dedicated to addressing unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. It specializes in the discovery and development of a new class of protein-like polymers, utilizing artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics. The company also provides materials science solutions to tackle challenges associated with peptide therapeutics, thereby facilitating researchers' access to innovative drugs in critical areas of healthcare.